Tenascin targeting appears to be one of the most promising RITs for glioblastoma, and many recent clinical trials using anti-tenascin 81C6 mAb showed similar results to the BC-2 and BC-4 mAbs. The gene discussed is TNC; the disease is glioblastoma.